anti cancer

SUTENT's activity against hard-to-treat tumors, particularly GIST and mRCC, both potentially life-threatening and with few, if any, other options," said Dr. John LaMattina, Pfizer president of worldwide research and development.

SUTENT is a highly selective, multi-targeted tyrosine kinase inhibitor that starves tumors of blood and nutrients needed for growth and simultaneously kills cancer cells that make up tumors.